Article Text

Download PDFPDF

4CPS-036 Is our protocol for the use of tocilizumab in COVID patients adequate?
  1. A Dominguez Barahona,
  2. S Gonzalez Suárez,
  3. MA Toledo Davia,
  4. C Blazquez Romero,
  5. L Torralba Fernandez,
  6. R Lopez Alvarez,
  7. C Jimenez Mendez,
  8. P Moya Gomez
  1. Hospital Virgen de la Salud, Hospitalary Pharmacy, Toledo, Spain


Background and importance Tocilizumab (TCZ) has been a key pillar in the management of pulmonary hyperinflammation in patients with SARS-CoV-2 pneumonia. The incessant publication of new studies assessing its effectiveness and the ideal time of use means that in-hospital protocols are constantly being reviewed and updated.

Aim and objectives To describe the clinical characteristics of hospitalised patients with SARS-CoV-2 pneumonia treated with TCZ and their evolution, and to compare our results with those of the primary endpoint (28-day mortality) of the RECOVERY study.

Material and methods Retrospective observational study of patients administered TCZ between October 2020 and February 2021 in a tertiary hospital. Criteria for TCZ use were PAFI <300 and meeting two of the following three criteria: C-reactive protein (CRP) >150 mg/L, D-dimer >1500 ng/mL and ferritin >2000 ng/mL, and not having contraindications for its use.

Each patient received a single dose of 400 mg if weight <75 kg and 600 mg if weight >75 kg.

Demographic data, comorbidities and days from symptom onset to TCZ administration were collected. Follow-up of analytical data (CRP, D-dimer and ferritin pre- and post- (15 days) TCZ administration). Clinical evolution was evaluated by mortality rate at 28 days.

Statistical analysis: Stata/MP v16.0. Student’s t-test was used for comparison of quantitative variables.

Results 39 patients were included, 25 (64.1%) were male, median age 74 (IQR 61–80) years. 61.5% had hypertension, 33.3% obesity, 41% diabetes mellitus, 17.9% chronic kidney disease, 12.8% heart disease. The median time from symptom onset to TCZ administration was 10 (IQR 7–15) days.

The medians prior to and at 15 days of TCZ administration were, respectively: 152.5 mg/L (IQR 89–220.8) and 1.7 mg/L (IQR 0.65–4.2) CRP (p<0.001); 2300 ng/mL (IQR 11 959–4889) and 1124 ng/mL (IQR 567–1439) D-dimer (p=0.1726); 1242 ng/mL (IQR 647–2705) and 851 ng/mL (IQR 268–1384) ferritin (p=0.1294). Mortality at 28 days was 64.1%.

Conclusion and relevance Our sample size is smaller than that of the RECOVERY study; however, the days of symptoms until TCZ administration (10 vs 9) and the median CRP prior to TCZ (143 vs 152.5 mg/L) in both studies are very similar. Our mortality is much higher (64.1% vs 29%). We found a statistically significant difference between our pre- and post-CRP data.

With this result, the in-hospital protocol was modified and new criteria for TCZ administration in COVID patients became oxygen saturation <92% or PAFI >300 and CRP >75 mg/L, with no contraindications for use.

In subsequent studies we will test whether this update helps to improve mortality outcomes.

Conflict of interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.